Gocovri Capsule, Coated Pellets
FDA Label NDC 17772-085

39 label sections · Submitted to the FDA by Supernus Pharmaceuticals, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Supernus Pharmaceuticals, Inc. for the product Gocovri (NDC 17772-085). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 dosing information, 2.2 administration information, 2.3 dosing in patients with renal impairment, 2.4 discontinuation and missed dose, 3 dosage forms and strengths, 4 contraindications, 5.1 falling asleep during activities of daily living and somnolence, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

5.6 Corneal Edema

Corneal edema has been reported in patients taking amantadine. Symptoms include sudden onset of blurry vision, or progressive vision loss, with or without eye pain. Corneal involvement is usually bilateral. Onset can occur from a few weeks to several years after starting amantadine. Resolution of symptoms typically begins within weeks of amantadine cessation. However, corneal grafts have been required in some patients when the condition is not recognized. Permanent damage can occur if amantadine is continued. Ask patients if their vision has changed and obtain ophthalmologic examinations to rule out corneal edema should vision changes occur after initiation of therapy with GOCOVRI. If corneal edema occurs, taper and discontinue GOCOVRI [see Dosage and Administration ( 2.4)] .

Principal Display Panel - 68.5 Mg Capsule Bottle Label

60 Capsules
NDC 17772-085-60

GOCOVRI ®
(amantadine) extended release capsules

68.5 mg

Rx only

Principal Display Panel (68.5 mg Capsule Bottle Label)

Principal Display Panel (68.5 mg Capsule Bottle Label)

Principal Display Panel - 137 Mg Capsule Bottle Label

60 Capsules
NDC 17772-170-60

GOCOVRI ®
(amantadine) extended release capsules

137 mg

Rx only

Principal Display Panel (137 mg Capsule Bottle Label)

Principal Display Panel (137 mg Capsule Bottle Label)

* Please review the disclaimer below.